Search

A skin-interfaced, miniaturized platform for triggered induction, capture and colorimetric multicomponent analysis of microliter volumes of sweat.

Barriers and facilitators to recruitment of underrepresented research participants: Perspectives of clinical research coordinators.

ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.

Late Diagnosis in the Era of Universal Newborn Screening Negatively Affects Short- and Long-Term Growth and Health Outcomes in Infants with Cystic Fibrosis.

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.

Wainwright, Claire; McColley, Susanna A; McNally, Paul; Powers, Michael; Ratjen, Felix; Rayment, Jonathan H; Retsch-Bogart, George; Roesch, Erica; Ahluwalia, Neil; Chin, Anna; Chu, Chenghao; Lu, Mengdi; Menon, Prema; Waltz, David; Weinstock, Tanya; Zelazoski, Laura; Davies, Jane C

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2 Through 5 Years with Cystic Fibrosis and at Least One F508del Allele.

Goralski, Jennifer L; Hoppe, Jordana E; Mall, Marcus A; McColley, Susanna A; McKone, Edward; Ramsey, Bonnie; Rayment, Jonathan H; Robinson, Phil; Stehling, Florian; Taylor-Cousar, Jennifer L; Tullis, Elizabeth; Ahluwalia, Neil; Chin, Anna; Chu, Chenghao; Lu, Mengdi; Niu, Tao; Weinstock, Tanya; Ratjen, Felix; Rosenfeld, Margaret

Anti-racist strategies for clinical and translational research: Design, implementation, and lessons learned from a new course.

Heard-Garris, Nia J; Brown, Jen F; Ewulonu, Uchenna C; Goel, Mita S; Gordon, Adam S; Henley, Candace; Khan, Sadiya S; Smith, Shawn M; McColley, Susanna A

Barriers to and solutions for representative inclusion across the lifespan and in life course research: The need for structural competency highlighted by the COVID-19 pandemic.

LeCroy, Madison N; Potter, Lindsey N; Bandeen-Roche, Karen; Bianco, Monica E; Cappola, Anne R; Carter, Ebony B; Dayan, Peter S; Eckstrom, Elizabeth; Edwards, Dorothy F; Farabi, Sarah S; Fisher, Sheehan D; Giordano, Judy; Hanson, Heidi A; Jenkins, Emerald; Juhn, Young; Kaskel, Frederick; Stake, Christine E; Reeds, Dominic N; Schleiss, Mark R; Wafford, Q Eileen; McColley, Susanna A

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.

Detection of disease-causing CFTR variants in state newborn screening programs.

McGarry, Meghan E; Ren, Clement L; Wu, Runyu; Farrell, Philip M; McColley, Susanna A

In response to "who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies".

Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening.

McColley, Susanna A; Martiniano, Stacey L; Ren, Clement L; Sontag, Marci K; Rychlik, Karen; Balmert, Lauren; Elbert, Alexander; Wu, Runyu; Farrell, Philip M